pubmed.ncbi.nlm.nih.gov

On the Pathogenesis of Alzheimer's Disease: The MAM Hypothesis - PubMed

Review

On the Pathogenesis of Alzheimer's Disease: The MAM Hypothesis

Estela Area-Gomez et al. FASEB J. 2017 Mar.

Abstract

The pathogenesis of Alzheimer's disease (AD) is currently unclear and is the subject of much debate. The most widely accepted hypothesis designed to explain AD pathogenesis is the amyloid cascade, which invokes the accumulation of extracellular plaques and intracellular tangles as playing a fundamental role in the course and progression of the disease. However, besides plaques and tangles, other biochemical and morphological features are also present in AD, often manifesting early in the course of the disease before the accumulation of plaques and tangles. These include altered calcium, cholesterol, and phospholipid metabolism; altered mitochondrial dynamics; and reduced bioenergetic function. Notably, these other features of AD are associated with functions localized to a subdomain of the endoplasmic reticulum (ER), known as mitochondria-associated ER membranes (MAMs). The MAM region of the ER is a lipid raft-like domain closely apposed to mitochondria in such a way that the 2 organelles are able to communicate with each other, both physically and biochemically, thereby facilitating the functions of this region. We have found that MAM-localized functions are increased significantly in cellular and animal models of AD and in cells from patients with AD in a manner consistent with the biochemical findings noted above. Based on these and other observations, we propose that increased ER-mitochondrial apposition and perturbed MAM function lie at the heart of AD pathogenesis.-Area-Gomez, E., Schon, E. A. On the pathogenesis of Alzheimer's disease: the MAM hypothesis.

Keywords: cholesterol; endoplasmic reticulum; lipid rafts; mitochondria; phospholipids.

© FASEB.

PubMed Disclaimer

Conflict of interest statement

This work was supported by the U.S. National Institutes of Health, National Institute on Aging (K01-AG045335; to E.A.-G.) and by the U.S. Department of Defense (W911F-15-1-0169), the Ellison Medical Foundation, and the J. Willard and Alice S. Marriott Foundation (all to E.A.S.).

Similar articles

Cited by

References

    1. Hardy J. A., Higgins G. A. (1992) Alzheimer’s disease: the amyloid cascade hypothesis. Science , 184–185 - PubMed
    1. Nunomura A., Perry G., Aliev G., Hirai K., Takeda A., Balraj E. K., Jones P. K., Ghanbari H., Wataya T., Shimohama S., Chiba S., Atwood C. S., Petersen R. B., Smith M. A. (2001) Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol. , 759–767 - PubMed
    1. Manczak M., Sheiko T., Craigen W. J., Reddy P. H. (2013) Reduced VDAC1 protects against Alzheimer’s disease, mitochondria, and synaptic deficiencies. J. Alzheimers Dis. , 679–690 - PMC - PubMed
    1. Fraser T., Tayler H., Love S. (2010) Fatty acid composition of frontal, temporal and parietal neocortex in the normal human brain and in Alzheimer’s disease. Neurochem. Res. , 503–513 - PubMed
    1. Pettegrew J. W., Panchalingam K., Hamilton R. L., McClure R. J. (2001) Brain membrane phospholipid alterations in Alzheimer’s disease. Neurochem. Res. , 771–782 - PubMed

Publication types

MeSH terms